Search 

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.

Private investment firm

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial disease that Pleiogenix is targeting is alcoholic hepatitis (AH), with additional diseases to follow (COVID-19, Fibrosis, and NASH) . AH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. The global and US prevalence is 20-25%. The AH market is estimated to be $1.2 Billion in 2025, having a current annual growth rate of 6% (2019-2025). There are no approved efficacious therapeutics for the prevention or treatment of AH (dexamethasone reduces inflammation). The target patients for therapy include those with moderate and severe forms of AH. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic, and multiple metabolic clinical benefits. In patients suffering from AH, inflammation is severely increased. In animal models of NASH, increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical that exhibits multiple beneficial effects, in the context of AH.

A publicly-traded bioceutical research, development and marketing firm with over 40 products backed by a combined $68 million in research and development and clinical studies. TRICCAR solutions support health challenges affecting over 6 billion people worldwide, beginning with four products to be introduced in 2021:

AVL™ - Antiviral immunity support
Global audience size: 6.2+ billion

CAL™ - Calcium deficiency
Global audience size: 6+ billion

OFF™ - Weight and obesity management
Global audience size: 1+ billion

CLM™ - Menopausal support
Global audience size: 500+ million

Having met 85%> effectiveness in placebo-based, double-blind studies, TRICCAR’s products are ready for market introduction as over-the-counter, direct-to-consumer bioceutical products. An additional 8 products will undergo Food and Drug Administration (FDA) approval. Our initial four products are targeted towards women, ages 25-65, yet appeal to all demographics and genders.

We sell via our patented and patent-pending direct-to-consumer marketing technologies that have historically generated $18 in revenue for every $1 spent compared to industry averages of $2 for every $1 spent. We add to these efforts with retail (ex. Walgreens, CVS, COSTCO, etc.) and online marketplaces (ex. Walmart.com, Amazon.com), and a 130,000 physician/chiropractor network.

Our Series B Convertible Preferred PIPE offering minimizes investor risk while providing significant potential upside. TRICCAR anticipates 3-year total revenue to exceed $163.2 million. Based on comparable price/sales valuations, this could indicate a market cap of approximately $403.5 million at time of conversion.

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

healthcare VC

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services